Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sangamo Therapeutics
(NQ:
SGMO
)
2.260
UNCHANGED
Streaming Delayed Price
Updated: 1:00 PM EST, Nov 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Sangamo Therapeutics
< Previous
1
2
3
4
5
Next >
J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
November 26, 2024
Via
Benzinga
Zeta Global, Spirit Airlines And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
November 12, 2024
Via
Benzinga
Earnings Scheduled For November 12, 2024
November 12, 2024
Via
Benzinga
Sangamo Therapeutics's Earnings Outlook
November 11, 2024
Via
Benzinga
Booz Allen Posts Upbeat Q3 Earnings, Joins Deckers Outdoor, Saia, Boyd Gaming And Other Big Stocks Moving Higher On Friday
October 25, 2024
Via
Benzinga
4 Analysts Have This To Say About Sangamo Therapeutics
October 23, 2024
Via
Benzinga
Why Is Sangamo Therapeutics (SGMO) Stock Up 52% Today?
August 06, 2024
Sangamo Therapeutics stock is heading higher on Tuesday as SGMO investors react to a new $50 million license agreement.
Via
InvestorPlace
Peering Into Sangamo Therapeutics's Recent Short Interest
July 25, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
October 23, 2024
Via
Benzinga
Nasdaq Turns Higher; Verizon Shares Fall After Q3 Results
October 22, 2024
Via
Benzinga
What's Going On With Sangamo Therapeutics Shares Tuesday?
October 22, 2024
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shares are moving higher Tuesday after the company announced the FDA approved an accelerated pathway for ST-920, a potential gene therapy for the treatment of...
Via
Benzinga
Exposures
Product Safety
Crude Oil Rises Sharply; 3M Posts Upbeat Earnings
October 22, 2024
Via
Benzinga
Exposures
Fossil Fuels
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 22, 2024
Via
Benzinga
4 Analysts Assess Sangamo Therapeutics: What You Need To Know
March 13, 2024
Via
Benzinga
Dow Falls Over 150 Points; General Motors Tops Q3 Views
October 22, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
FDA Approves Pfizer's Second Hemophilia Drug With Six Months
October 14, 2024
Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly treatment reduces bleeding rates and offers convenience via an...
Via
Benzinga
Exposures
Product Safety
Why Sangamo Therapeutics Stock Is Soaring
August 06, 2024
Sangamo Therapeutics shares are trading higher Tuesday after the company announced it has entered into a license agreement with Genentech to develop intravenously administered genomic medicines for...
Via
Benzinga
Why Is Sangamo Therapeutics (SGMO) Stock Up 40% Today?
July 24, 2024
Little-known firm Sangamo Therapeutics is surging today, with SGMO stock up more than 40% on promising late-stage trial results.
Via
InvestorPlace
Crude Oil Gains 1%; AT&T Shares Rise After Q2 Earnings
July 24, 2024
Via
Benzinga
Exposures
Fossil Fuels
Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
July 26, 2024
Via
Benzinga
Dow Tumbles 300 Points; Tesla Shares Plunge After Q2 Results
July 24, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
July 24, 2024
Via
Benzinga
Sangamo Stock Spikes As Pfizer Partnership Meets Goal In Late-Stage Study
July 24, 2024
Pfizer's Phase 3 AFFINE study of giroctocogene fitelparvovec gene therapy for hemophilia A meets key endpoints, showing a significant reduction in annualized bleeding rate.
Via
Benzinga
Critical Insights From Sangamo Therapeutics Analyst Ratings: What You Need To Know
May 15, 2024
Via
Benzinga
SGMO Stock Earnings: Sangamo Therapeutics Misses EPS, Misses Revenue for Q1 2024
May 09, 2024
SGMO stock results show that Sangamo Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
12 Health Care Stocks Moving In Friday's Intraday Session
March 22, 2024
Via
Benzinga
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform
March 19, 2024
Unlock potential with Voyager Therapeutics as HC Wainwright initiates coverage highlights its TRACER capsid platform, promising CNS-targeted gene therapies and strategic partnerships driving long-term...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
February 19, 2024
Via
Benzinga
Earnings Scheduled For March 13, 2024
March 13, 2024
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
February 12, 2024
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.